316 related articles for article (PubMed ID: 26600980)
1. Promising biological therapies for ulcerative colitis: A review of the literature.
Akiho H; Yokoyama A; Abe S; Nakazono Y; Murakami M; Otsuka Y; Fukawa K; Esaki M; Niina Y; Ogino H
World J Gastrointest Pathophysiol; 2015 Nov; 6(4):219-27. PubMed ID: 26600980
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. Current new challenges in the management of ulcerative colitis.
Fukuda T; Naganuma M; Kanai T
Intest Res; 2019 Jan; 17(1):36-44. PubMed ID: 30678445
[TBL] [Abstract][Full Text] [Related]
4. Update on the Use of Biologic Therapy in Ulcerative Colitis.
Aggarwal A; Sabol T; Vaziri H
Curr Treat Options Gastroenterol; 2017 Mar; 15(1):155-167. PubMed ID: 28120279
[TBL] [Abstract][Full Text] [Related]
5. The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom.
Lindsay JO; Picker N; Kromer D; Smyth M; Patel H
Curr Med Res Opin; 2023 May; 39(5):681-689. PubMed ID: 36951899
[TBL] [Abstract][Full Text] [Related]
6. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease.
Cherry LN; Yunker NS; Lambert ER; Vaughan D; Lowe DK
Ther Adv Chronic Dis; 2015 Sep; 6(5):224-33. PubMed ID: 26336591
[TBL] [Abstract][Full Text] [Related]
8. P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
Parra Izquierdo V; Frias-Ordoñez J; Galindo P; Romero-Sanchez C; Florez C
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S14-S15. PubMed ID: 37461974
[TBL] [Abstract][Full Text] [Related]
9. Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?
Allocca M; Fiorino G; Gilardi D; Preatoni P; Papa A; Peyrin-Biroulet L; Danese S
Curr Drug Targets; 2018; 19(7):748-756. PubMed ID: 27231106
[TBL] [Abstract][Full Text] [Related]
10. Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease.
Wilson M; Lucas A; Cameron A; Luo M
Am Health Drug Benefits; 2018 Jul; 11(5):253-262. PubMed ID: 30464793
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging biologics for ulcerative colitis.
Park SC; Jeen YT
Gut Liver; 2015 Jan; 9(1):18-27. PubMed ID: 25547087
[TBL] [Abstract][Full Text] [Related]
12. Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis.
Pugliese D; Felice C; Landi R; Papa A; Guidi L; Armuzzi A
Drug Healthc Patient Saf; 2016; 8():1-7. PubMed ID: 26893582
[TBL] [Abstract][Full Text] [Related]
13. Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.
Lichtenstein GR; Hanauer SB; Sandborn WJ
Gastroenterol Hepatol (N Y); 2015 Mar; 11(3 Suppl 1):1-16. PubMed ID: 26491415
[TBL] [Abstract][Full Text] [Related]
14. Golimumab for the treatment of ulcerative colitis.
Flamant M; Paul S; Roblin X
Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
[TBL] [Abstract][Full Text] [Related]
15. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists.
Fausel R; Afzali A
Ther Clin Risk Manag; 2015; 11():63-73. PubMed ID: 25609972
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.
Vande Casteele N; Khanna R
Pharm Res; 2017 Aug; 34(8):1556-1563. PubMed ID: 28374338
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
Davis R; McParland P; Dodd S; Storey D; Probert C; Collins P; Skouras T; Steel A; Derbyshire E; Dibb M; Subramanian S
Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):661-667. PubMed ID: 30855421
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Wu B; Wang Z; Zhang Q
Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.
Thukral C; Cheifetz A; Peppercorn MA
Drugs; 2006; 66(16):2059-65. PubMed ID: 17112300
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
